We are involved in a number of research collaborations with major pharmaceutical companies. These range from early stage research establishing target tractability through to late lead optimisation programs. We value close co-operation with our collaborators to ensure the combined strengths of the partners are most effectively deployed to deliver drug candidates.
Current disclosed collaborations include
- Servier, two development stage collaborations on Bcl-2 family of proteins and two further research collaborations on undisclosed oncology targets
- Lundbeck, a research collaboration targetting LRRK2
- Asahi Kasei Pharmaceuticals, a research collaboration targetting Rheumatoid Arthritis
- Daiichi Sankyo Company, a research collaboration on undisclosed oncology targets